Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan approves ZymeTx' ZstatFlu test:

This article was originally published in Clinica

Executive Summary

ZymeTx has received the go-ahead to market its rapid, point-of-care influenza test, ZstatFlu, in Japan. Clinical trials have shown that the 20-minute, throat-swab-based test can detect both influenza types A and B with a specificity of 99%, says the Oklahoma City, Oklahoma company. The test has also detected variant strains, such as the Hong Kong flu. ZymeTx' CEO Norman Proulx, says that Japan represents the largest market for the test outside the US, where it has been available since 1998. The product will be distributed by Japanese firm, Nichirei.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts